Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.

TL;DR: In this paper, the safety and immunogenicity of the BNT162b2 (Pfizer-BioNTech) vaccine in patients with cancer was evaluated using data from three London hospitals between Dec 8, 2020 and Feb 18, 2021.

TL;DR: In this article, the authors found that recurrent deletions overcome this slow substitution rate and accelerate SARS-CoV-2 antigenic evolution and may, more generally, drive adaptive evolution.

TL;DR: In this article, the authors identified an emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the western United States.

TL;DR: In this article, the authors map all the mutations to the SARS-CoV-2 spike receptor-binding domain (RBD) that escape binding by a leading monoclonal antibody, LY-coV555, and its cocktail combination with LY CoV016.

TL;DR: It is estimated that 44% (95% confidence interval, 25–69%) of secondary cases were infected during the index cases’ presymptomatic stage, in settings with substantial household clustering, active case finding and quarantine outside the home.

TL;DR: This work investigated the development of resistance against four antibodies to the spike protein that potently neutralize SARS-CoV-2, individually as well as when combined into cocktails.

TL;DR: It is demonstrated suppressive but not curative effect of remdesivir in an immunocompromised patient treated with chemoimmunotherapy for chronic lymphocytic leukemia experienced a 9-week course of COVID-19 with high fever and severe viral pneumonia.

TL;DR: Evidence supports a causative relationship between PAPS, pulmonary capillaritis, and DAH in the absence of thromboembolic disease, and a possible nonthrombotic mechanism of antiphospholipid antibody-mediated pathology is needed to guide future therapies for this unusual manifestation of PAPS.